Arterial stiffness as surrogate end point: Needed clinical trials

Hypertension

Volumn 60, Issue 2, 2012, Pages 518-522

  Laurent, Stéphane ^a   Briet, Marie ^a   Boutouyrie, Pierre ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; TROPONIN I;

AGING; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; HEART LEFT VENTRICLE MASS; HUMAN; MICROALBUMINURIA; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN SUBSTRATE; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84864286433     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.194456     Document Type: Conference Paper

References (32)

1. Mancia G, de Backer G, Cifkova R, Dominiczak A, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder R, Struijker Boudier HA, Zanchetti A. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH). J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
2. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011;123:551-565.
3. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier . Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605. (Pubitemid 44627304)
4. Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: A review of methods for estimating health impact. Circulation. 2011;123: 1116-1124.
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847. (Pubitemid 28213628)
6. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, for the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987-1003. (Pubitemid 36712275)
7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
8. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639. (Pubitemid 44969122)
9. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116. (Pubitemid 351679597)
10. Nilsson P, Boutouyrie P, Laurent S. Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54:3-10.
11. Laurent S, Briet M, Boutouyrie P. Large/small artery cross talk and recent morbidity mortality trials in hypertension. Hypertension. 2009;54: 388-392.
12. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC Jr, Wilson PW, for the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation. 2009;119: 2408-2416.
13. Safar ME. Arterial aging-hemodynamic changes and therapeutic options. Nat Rev Cardiol. 2010;7:442-449.
14. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46: 194-199. (Pubitemid 40946513)
15. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-Analysis. J Am Coll Cardiol. 2010;55:1318-1327.
16. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension. 2002;39:10-15. (Pubitemid 34098081)
17. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC. Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study. Circulation. 2006;113:657-663.
18. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens. 2009;27:2351-2357.
19. Mitchell GF, Hwang SJ, Vasan RD, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation. 2010;121:505-511.
20. Ben Schlomo Y, Spears M, Boustred C, May M, Anderson S, Boutouyrie P, Cameron J, Chen CH, Cockcroft J, Cruickshank K, Hwang SJ, Lakatta E, Laurent S, Maldonado J, McEniery CM, Mitchell G, Najjar S, Newman A, Ohishi M, Pannier B, Pereira T, Shokawa T, Sutton-Tyrell K, Webb D, Willum-Hansen T, Zoungas S, Wilkinson IB. Predictive value of pulse wave velocity for cardiovascular events in 15,220 subjects: an individual participant meta-Analysis on behalf of the PWV collaborative group. J Hypertens. 2010;28(suppl A)E446.
21. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;20:103:987-992. (Pubitemid 32183805)
22. Mancia G, Laurent S, Agabiti-Rosei E, ambrosioni E, Burnier M, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Kjeldsen S, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen M, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder R, Struijker-Boudier HAJ, van Zwieten P, Vigiimaa M, Zanchetti A. Guidelines on hypertension management revisited in 2009: an ESH position statement. J Hypertens. 2009;27:2121-2158.
23. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445-448.
24. Boutouyrie P, Lacolley P, Briet M, Regnault V, Stanton A, Laurent S, Mahmud A. Pharmacological modulation of arterial stiffness. Drugs. 2011;71:1689-1701.
25. Ong KT, Delerme S, Pannier B, Safar M, Benetos A, Laurent S, Boutouyrie P. Aortic stiffness is reduced beyond blood pressure lowering by short-And long-term antihypertensive treatment: A meta-Analysis of individual data in 294 patients. J Hypertens 2011,29;1034-1042.
26. Ait-Oufella H, Collin C, Bozec E, Laloux B, Ong KT, Dufouil C, Boutouyrie P, Laurent S. Long-term reduction in aortic stiffness: A 5.3-year follow-up in routine clinical practice. J Hypertens. 2010;28:2336-2341.
27. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48:80-86. (Pubitemid 44313590)
28. Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA, for the Prevention of Events With Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: The Prevention of Events With Angiotensin-Converting Enzyme Inhibition Hemodynamic Substudy. Hypertension. 2007;49:1271-1217.
29. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial. J Am Coll Cardiol. 2009;54:505-512.
30. Ong KT, Perdu J, Plauchu H, De Backer J, Emmerich J, Jeunemaitre X, Germain DP, Collignon P, Georgesco G, Bozec E, Hulot JS, Laurent S, Boutouyrie P. Effect of celiprolol on prevention of cardiovascular events in Ehlers-Danlos type IV, the vascular type. Lancet. 2010;376:1476-1484.
31. Rennenberg RJM, Schurgers LJ, Kroon AA, Stehouwer CDA. Arterial calcifications. J Cell Mol Med. 2010;14:2203-2210.
32. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292:2350-2356. (Pubitemid 39491919)